Overcoming Depression with 5-HT2A Receptor Ligands
Agata Zięba1, Piotr Stępnicki1, Dariusz Matosiuk1
1Department of Synthesis and Chemical Technology of Pharmaceutical Substances with Computer Modeling Laboratory, Faculty of Pharmacy, Medical University of Lublin, 4A Chodźki St., PL-20093 Lublin, Poland.
International Journal of Molecular Sciences
|January 11, 2022
Summary
Novel antidepressant drugs targeting the serotonin 2A (5-HT2A) receptor show promise for treating depression. Research highlights the receptor's role and explores new drug candidates for improved therapies.
Area of Science:
- Neuroscience
- Pharmacology
- Medicinal Chemistry
Background:
- Depression is a complex disorder with limited treatment efficacy.
- Current therapies do not offer complete cures, necessitating novel therapeutic strategies.
- The serotonin 2A (5-HT2A) receptor is implicated in depression's pathophysiology.
Purpose of the Study:
- To review the role of 5-HT2A receptor modulators in depression treatment.
- To provide insights into the structural and physiological aspects of the 5-HT2A receptor.
- To summarize recent advancements in identifying and synthesizing 5-HT2A receptor ligands.
Main Methods:
- Literature search on PubMed and Google Scholar for relevant studies.
- Critical assessment of articles based on titles and abstracts.
- Inclusion of studies detailing 5-HT2A receptor function and therapeutic potential.
Main Results:
- The 5-HT2A receptor's significance in depression is highlighted.
- Virtual screening campaigns have identified potential novel ligands.
- Newly synthesized compounds acting on the 5-HT2A receptor are presented.
Conclusions:
- 5-HT2A receptor signaling modulators represent a promising avenue for depression treatment.
- Understanding the 5-HT2A receptor's structure and function aids drug design.
- Continued research into novel ligands may lead to more effective and safer antidepressants.
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
410
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
410
01:25Antidepressant Drugs: Overview
865
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
865
01:21G-protein Coupled Receptors
123.7K
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
123.7K
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
715
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
715
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
380
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
380
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.3K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.3K